Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9441)	3/30/1999 9:52:00 AM
From: Bluegreen	Respond to of 17367

Bob, until we know more about the GNE and XOMA future relationship, I'd cool it. Those disclaimers may become worthless under heat.

To: Robert K. who wrote (9441)	3/30/1999 1:50:00 PM
From: aknahow	Respond to of 17367

Robert, when you view this patent do browser search for XOMA. They have license agreement for one product described. United States Patent 5,885,808 Spooner , et al. March 23, 1999 Adenovirus with modified binding moiety specific for the target cells Abstract An adenovirus or adenovirus-like particle which has a modified binding specificity conferred by a binding moiety. The binding moiety is heterologous to the adenovirus and is incorporated as a fusion protein with the fiber protein. This allows the adenovirus or adenovirus-like particle to bind to a target cell which is not the natural host cell of the virus. The penton fiber is modified by the insertion or, deletion, or substitution of amino acid residues, that disrupt the host-cell binding function so that the adenovirus or adenovirous like particle does not bind the natural host cell.